WuXi Biologics Sees Remarkable Revenue Increase and Project Expansion in H1 2026

WuXi Biologics Reports Strong Profitable Growth in H1 2026

WuXi Biologics (Cayman) Inc., renowned as a premier global Contract Research, Development, and Manufacturing Organization (CRDMO), recently released its interim results for the first half of 2026. The company has showcased extraordinary revenue growth, which reflects its expansive project involvement in the evolving biotechnology landscape.

Financial Performance

In H1 2026, WuXi Biologics recorded a total revenue of RMB 11.8 billion, marking an 18.4% increase year-over-year, translating to a 23.4% surge in USD terms. This growth has been fueled by a robust demand for new Investigational New Drug (IND)-enabling programs, alongside the successful advancement of existing projects through late-stage development and commercial manufacturing.

The financial highlights also reveal a significant increase in the IFRS gross profit margin, which grew to 46.2%, an increase of 350 basis points compared to the previous year. This success can be attributed to the continued operating leverage, enhanced capacity utilization, and advancements driven through the WuXi Biologics Business System (WBS) and digital initiatives in operations.

Adjusted net profit surged by an impressive 38.6% year-over-year to RMB 3.9 billion, validating the Group's strategic focus on high-margin projects. Notably, adjusted earnings per share saw an increase of 37.3% to RMB 0.81, a noteworthy achievement signaling a strong return on investment for stakeholders.

Project Expansion and New Developments

WuXi Biologics has shown exceptional growth in its project pipeline, adding a record-high of 169 integrated projects in H1 2026. This includes 123 organic projects— a remarkable 43% increase from the previous year. The recent acquisition of WuXi XDC's BioDlink accounted for an additional 46 integrated projects, reflecting the Group's strategic evolution and focus on complex biologics modalities.

This robust expansion provides a promising outlook for future revenues, with a backlog totaling USD 25.1 billion, inclusive of USD 12.6 billion in service backlog, signifying the Group's strong future revenue visibility. With 78 projects currently in Phase III and 28 in commercial manufacturing, WuXi Biologics continues to strengthen its leadership position in the global biopharmaceutical market.

The company emphasizes its dedication to innovation, showcasing advancements such as the WuXia™ TrueSite platform. Launched in October 2025, this platform has already been adopted in over 70 projects, further enhancing the Group's capability to expedite development timelines and increase productivity. The platform’s ability to deliver high titers for monoclonal antibodies and bi-specifics represents a critical competitive advantage, particularly in the biosimilars sector.

Additionally, WuXi Biologics’ commitment to sustainability remains central to its operational strategy. As the focus on environmentally responsible practices intensifies globally, the Group’s recognition by leading ESG rating agencies underscores its commitment to creating positive social and environmental impacts.

Looking Forward

With a target to expand its IND filing capacity by 50% to 300 filings annually by 2027, WuXi Biologics is well-positioned to capitalize on emerging opportunities in drug discovery and next-generation therapeutic platforms. The expansion is underpinned by plans to continue investing in talent and technology, fortifying its leadership in biologics innovation.

Dr. Chris Chen, CEO of WuXi Biologics, expressed confidence in the Group's trajectory, stating that their technology differentiation has started translating into competitive commercial advantages. The combination of advanced technologies and strategic global expansions ensures that WuXi Biologics remains at the forefront of biopharmaceutical solutions.

As the demand for biologics escalates and the complexity of projects increases, WuXi Biologics is committed to its mission of making every biologic possible while delivering exceptional value to its clients and stakeholders. The journey of H1 2026 only reinforces the Group’s foundational strength, paving the way for sustained growth in the future.